Publications
147
Citations
2,791
Est. group size
~34
Recurring co-author estimate
Active years
29
Publishing since 1998
Beth Christian's research focuses on clinical trials for lymphoma, particularly Hodgkin lymphoma and various B-cell lymphomas, testing new drug combinations such as antibody-drug conjugates, immune checkpoint inhibitors (like pembrolizumab and nivolumab), and targeted therapies (like brentuximab vedotin and acalabrutinib). This work involves multicenter clinical studies aimed at improving treatment options for patients with relapsed, refractory, or previously untreated lymphomas, and also contributes to national treatment guideline development.
Publication output has grown over the last decade, rising from single-digit annual counts around 2017-2020 to a peak of around 15-19 publications per year in 2023-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results
Blood Advances · 2025
- Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results
Blood · 2024
- Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open‐label study
British Journal of Haematology · 2024
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170
Blood · 2023
- NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Journal of the National Comprehensive Cancer Network · 2023
- Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial
Blood · 2022
- P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
HemaSphere · 2022
- Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Blood · 2021
- NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Journal of the National Comprehensive Cancer Network · 2021
- Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Blood · 2021
- Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) RU051505I.
Journal of Clinical Oncology · 2020
- Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study
Blood · 2020
- A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results
Blood · 2020
- Pembrolizumab in relapsed or refractory Richter syndrome
British Journal of Haematology · 2020
- Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
The Lancet Haematology · 2020
- Blood×46
- Blood Advances×11
- Journal of Clinical Oncology×7
- Transplantation and Cellular Therapy×6
- Journal of the National Comprehensive Cancer Network×5
- David A. Bond
Medicine · The Ohio State University
- Narendranath Epperla
Medicine · The Ohio State University
- Timothy Voorhees
Medicine · The Ohio State University
- Kaitlin Annunzio
Medicine · The Ohio State University
- Kami J. Maddocks
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile